Skip to Content
Merck
CN

Key Documents

View All Documentation

SML3799

Nilotinib

≥98% (HPLC)

Synonym(s):

4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl]benzamide, 4-Methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-benzamide, AMN 107, AMN107

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View

About This Item

Empirical Formula (Hill Notation):
C28H22F3N7O
CAS Number:
641571-10-0
Molecular Weight:
529.52
UNSPSC Code:
12352200
NACRES:
NA.21
MDL number:
MFCD09833716
Assay:
≥98% (HPLC)
Form:
powder
Quality level:
100
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Quality Level

100

assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 2 mg/mL, clear (Warmed)

storage temp.

2-8°C

SMILES string

FC(F)(F)c1cc(cc(c1)NC(=O)c3cc(c(cc3)C)Nc4nc(ccn4)c5cnccc5)[n]2cnc(c2)C

InChI

1S/C28H22F3N7O/c1-17-5-6-19(10-25(17)37-27-33-9-7-24(36-27)20-4-3-8-32-14-20)26(39)35-22-11-21(28(29,30)31)12-23(13-22)38-15-18(2)34-16-38/h3-16H,1-2H3,(H,35,39)(H,33,36,37)

InChI key

HHZIURLSWUIHRB-UHFFFAOYSA-N

Biochem/physiol Actions

Nilotinib (AMN107) is an orally available, selective and potent ATP-competitive wild-type and mutant Bcr-Abl kinase inhibitor that is 10-30-fold more potent than imatinib. Nilotinib is used to treat Philadelphia chromosome (Ph+)-positive chronic myelogenous leukemia (CML). Nilotinib reduces midbrain Bcr-Abl autophosphorylation, amyloid-β levels, and neuronal loss, as well as improves autophagosome clearance and reverses cognitive deficits in the Tg2576 transgenic mouse model of Alzheimer’s disease.
Orally available, selective and potent ATP-competitive wild-type and mutant Bcr-Abl kinase inhibitor

Still not finding the right product?

Explore all of our products under Nilotinib

pictograms

Health hazard
GHS08

signalword

Danger

hcodes

H372,H413

Hazard Classifications

Aquatic Chronic 4 - STOT RE 1

target_organs

Liver,Kidney,gallbladder

Storage Class

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk

WGK 2

flash_point_f

Not applicable

flash_point_c

Not applicable

Regulatory Information

新产品

This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000444080
0000444080
0000380469
0000380469
0000265098

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl
Cancer Cell, 7(2), 129-141 (2005)
Livia La Barbera et al.
Progress in neurobiology, 202, 102031-102031 (2021-03-09)
What happens precociously to the brain destined to develop Alzheimer's Disease (AD) still remains to be elucidated and this is one reason why effective AD treatments are missing. Recent experimental and clinical studies indicate that the degeneration of the dopaminergic
Tomer Meirson et al.
Oncotarget, 9(31), 22158-22183 (2018-05-19)
Metastatic dissemination of cancer cells from the primary tumor and their spread to distant sites in the body is the leading cause of mortality in breast cancer patients. While researchers have identified treatments that shrink or slow metastatic tumors, no

Global Trade Item Number

SKUGTIN
SML3799-10MG04065270218278
SML3799-50MG04065270218285